Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Ryan K. Shields; Erin K. McCreary; Rachel V. Marini; Ellen G. Kline; Chelsea E. Jones; Binghua Hao; Liang Chen; Barry N. Kreiswirth; Yohei Doi; Cornelius J. Clancy; M. Hong Nguyen

doi:10.1093/cid/ciz1131

Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Ryan K. Shields, Erin K. McCreary, Rachel V. Marini, Ellen G. Kline, Chelsea E. Jones, Binghua Hao, Liang Chen, Barry N. Kreiswirth, Yohei Doi, Cornelius J. Clancy, M. Hong Nguyen

Microbiology

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

Original language	English
Pages (from-to)	667-671
Number of pages	5
Journal	Clinical Infectious Diseases
Volume	71
Issue number	3
DOIs	https://doi.org/10.1093/cid/ciz1131
Publication status	Published - 01-08-2020

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciz1131

Fingerprint Dive into the research topics of 'Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections'. Together they form a unique fingerprint.

Cite this

Shields, Ryan K. ; McCreary, Erin K. ; Marini, Rachel V. ; Kline, Ellen G. ; Jones, Chelsea E. ; Hao, Binghua ; Chen, Liang ; Kreiswirth, Barry N. ; Doi, Yohei ; Clancy, Cornelius J. ; Nguyen, M. Hong. / Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections. In: Clinical Infectious Diseases. 2020 ; Vol. 71, No. 3. pp. 667-671.

@article{4fd3c07041154441bfde9a924498c076,

title = "Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections",

abstract = "Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.",

author = "Shields, {Ryan K.} and McCreary, {Erin K.} and Marini, {Rachel V.} and Kline, {Ellen G.} and Jones, {Chelsea E.} and Binghua Hao and Liang Chen and Kreiswirth, {Barry N.} and Yohei Doi and Clancy, {Cornelius J.} and Nguyen, {M. Hong}",

year = "2020",

month = aug,

day = "1",

doi = "10.1093/cid/ciz1131",

language = "English",

volume = "71",

pages = "667--671",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections. / Shields, Ryan K.; McCreary, Erin K.; Marini, Rachel V.; Kline, Ellen G.; Jones, Chelsea E.; Hao, Binghua; Chen, Liang; Kreiswirth, Barry N.; Doi, Yohei; Clancy, Cornelius J.; Nguyen, M. Hong.

In: Clinical Infectious Diseases, Vol. 71, No. 3, 01.08.2020, p. 667-671.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

AU - Shields, Ryan K.

AU - McCreary, Erin K.

AU - Marini, Rachel V.

AU - Kline, Ellen G.

AU - Jones, Chelsea E.

AU - Hao, Binghua

AU - Chen, Liang

AU - Kreiswirth, Barry N.

AU - Doi, Yohei

AU - Clancy, Cornelius J.

AU - Nguyen, M. Hong

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

AB - Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

UR - http://www.scopus.com/inward/record.url?scp=85088848147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088848147&partnerID=8YFLogxK

U2 - 10.1093/cid/ciz1131

DO - 10.1093/cid/ciz1131

M3 - Article

C2 - 31738396

AN - SCOPUS:85088848147

VL - 71

SP - 667

EP - 671

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -